Physician profile
Jonathan Rhee
NPI 1689838542
$3,249.67
in general payments reported to CMS, 2019-2025
20 companies · $85.59 in 2025
The $85.59 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $1,006 · 2021: $277 · 2022: $739 · 2023: $364 · 2025: $85.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $612.76 | 2019-2023 | Cardiomems |
| Boston Scientific Corporation | $470.37 | 2019-2022 | |
| Penumbra, INC. | $404.60 | 2020-2023 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $317.31 | 2020-2023 | Lifevest |
| Medtronic Vascular, INC. | $192.78 | 2019-2020 | |
| Cardiovascular Systems INC. | $158.71 | 2019-2020 | |
| Edwards Lifesciences Corporation | $156.79 | 2019-2020 | |
| Abiomed | $151.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $131.97 | 2019-2020 | |
| Shockwave Medical, INC | $101.90 | 2022 | |
| Bard Peripheral Vascular, INC. | $90.83 | 2022 | |
| Sumitomo Pharma America, INC. | $85.59 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $55.35 | 2020-2021 | |
| Medtronic, INC. | $51.21 | 2022-2023 | Abre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $50.13 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $45.70 | 2020 | |
| Amgen INC. | $44.93 | 2020-2021 | |
| Philips North America LLC | $35.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.